The ACT NOW study examined whether treatment of impaired glucose tolerance in pre-diabetic patients with pioglitazone could prevent or delay the development of type 2 diabetes. Join host Dr. Steven Edelman and his guest, endocrinologist and professor of medicine at the University of California San Diego, Dr. Robert Henry, as they discuss the results and implications for clinical care.
ReachMD
Be part of the knowledge.™Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Interventions Targeting Impaired Glucose Tolerance
Share this program on:
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
Presenters
Recommended
Details
Presenters
Comments
Recommended
Overview
The ACT NOW study examined whether treatment of impaired glucose tolerance in pre-diabetic patients with pioglitazone could prevent or delay the development of type 2 diabetes. Join host Dr. Steven Edelman and his guest, endocrinologist and professor of medicine at the University of California San Diego, Dr. Robert Henry, as they discuss the results and implications for clinical care.
Presenters
Facebook Comments